z-logo
open-access-imgOpen Access
Inactivation of CES1 Blocks Prostaglandin D2 Glyceryl Ester Catabolism in Monocytes/Macrophages and Enhances Its Anti-inflammatory Effects, Whereas the Pro-inflammatory Effects of Prostaglandin E2 Glyceryl Ester Are Attenuated
Author(s) -
Hannah L. Scheaffer,
Abdolsamad Borazjani,
Brittany N. Szafran,
Matthew K. Ross
Publication year - 2020
Publication title -
acs omega
Language(s) - English
Resource type - Journals
ISSN - 2470-1343
DOI - 10.1021/acsomega.0c03961
Subject(s) - prostaglandin , chemistry , prostaglandin d2 , monoacylglycerol lipase , catabolism , endocannabinoid system , inflammation , metabolism , biochemistry , prostaglandin e , monocyte , pharmacology , biology , immunology , receptor
Human monocytic cells in blood have important roles in host defense and express the enzyme carboxylesterase 1 (CES1). This metabolic serine hydrolase plays a critical role in the metabolism of many molecules, including lipid mediators called prostaglandin glyceryl esters (PG-Gs), which are formed during cyclooxygenase-mediated oxygenation of the endocannabinoid 2-arachidonoylglycerol. Some PG-Gs have been shown to exhibit anti-inflammatory effects; however, they are unstable compounds, and their hydrolytic breakdown generates pro-inflammatory prostaglandins. We hypothesized that by blocking the ability of CES1 to hydrolyze PG-Gs in monocytes/macrophages, the beneficial effects of anti-inflammatory prostaglandin D 2 -glyceryl ester (PGD 2 -G) could be augmented. The goals of this study were to determine whether PGD 2 -G is catabolized by CES1, evaluate the degree to which this metabolism is blocked by small-molecule inhibitors, and assess the immunomodulatory effects of PGD 2 -G in macrophages. A human monocytic cell line (THP-1 cells) was pretreated with increasing concentrations of known small-molecule inhibitors that block CES1 activity [chlorpyrifos oxon (CPO), WWL229, or WWL113], followed by incubation with PGD 2 -G (10 μM). Organic solvent extracts of the treated cells were analyzed by liquid chromatography with tandem mass spectrometry to assess levels of the hydrolysis product PGD 2 . Further, THP-1 monocytes with normal CES1 expression (control cells) and "knocked-down" CES1 expression (CES1KD cells) were employed to confirm CES1's role in PGD 2 -G catabolism. We found that CES1 has a prominent role in PGD 2 -G hydrolysis in this cell line, accounting for about 50% of its hydrolytic metabolism, and that PGD 2 -G could be stabilized by the inclusion of CES1 inhibitors. The inhibitor potency followed the rank order: CPO > WWL113 > WWL229. THP-1 macrophages co-treated with WWL113 and PGD 2 -G prior to stimulation with lipopolysaccharide exhibited a more pronounced attenuation of pro-inflammatory cytokine levels (interleukin-6 and TNFα) than by PGD 2 -G treatment alone. In contrast, prostaglandin E 2 -glyceryl ester (PGE 2 -G) had opposite effects compared to those of PGD 2 -G, which appeared to be dependent on the hydrolysis of PGE 2 -G to PGE 2 . These results suggest that the anti-inflammatory effects induced by PGD 2 -G can be further augmented by inactivating CES1 activity with specific small-molecule inhibitors, while pro-inflammatory effects of PGE 2 -G are attenuated. Furthermore, PGD 2 -G (and/or its downstream metabolites) was shown to activate the lipid-sensing receptor PPARγ, resulting in altered "alternative macrophage activation" response to the Th2 cytokine interleukin-4. These findings suggest that inhibition of CES1 and other enzymes that regulate the levels of pro-resolving mediators such as PGD 2 -G in specific cellular niches might be a novel anti-inflammatory approach.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.
Having issues? You can contact us here
Accelerating Research

Address

John Eccles House
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom